Literature DB >> 21830019

Essential thrombocytosis and antiphospholipid antibody syndrome causing chronic Budd-Chiari syndrome.

Dinesh Yadav1, Jagdish Chandra, Sunita Sharma, Varinder Singh.   

Abstract

Essential thrombocytosis is extremely rare in children. However, when present, it is associated with increased prevalence of antiphospholipid antibodies and thrombo-hemorrhagic complications. The authors report here a child with Budd-Chiari Syndrome resulting from essential thrombocytosis and associated antiphospholipid antibodies. A 13- y-old boy presented with microcytic hypochromic anemia, hepatosplenomegaly and thrombocytosis. CT scan demonstrated calcified thrombus in inferior vena cava (IVC). Diagnosis of essential thrombocytosis was considered in view of persistent thrombocytosis, antiphospholipid antibodies, bone marrow showing increased number, clusters and giant forms of megakaryocytes and IVC thrombosis. He was started on warfarin prophylaxis and did not have thrombotic recurrence on follow up.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21830019     DOI: 10.1007/s12098-011-0550-6

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  10 in total

Review 1.  Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.

Authors:  Monica Galli; Davide Luciani; Guido Bertolini; Tiziano Barbui
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

2.  Management of polycythemia vera and essential thrombocythemia.

Authors:  Peter J Campbell; Anthony R Green
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

Review 3.  Primary and secondary thrombocytosis in childhood.

Authors:  Christof Dame; Anton Heinz Sutor
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

4.  Thrombosis and the antiphospholipid syndrome.

Authors:  Thomas L Ortel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

5.  Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis.

Authors:  C N Harrison; S Donohoe; P Carr; M Dave; I Mackie; S J Machin
Journal:  Thromb Haemost       Date:  2002-05       Impact factor: 5.249

Review 6.  Antiphospholipid syndrome.

Authors:  Angelo Ravelli; Alberto Martini
Journal:  Pediatr Clin North Am       Date:  2005-04       Impact factor: 3.278

Review 7.  Update on the classification, assessment of prognosis and therapy of Budd-Chiari syndrome.

Authors:  Marco Senzolo; Evangelos C Cholongitas; David Patch; Andrew K Burroughs
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2005-04

Review 8.  Antiphospholipid syndrome as the second cause of non-tumorous Budd-Chiari syndrome.

Authors:  S Pelletier; B Landi; J C Piette; P Ekert; A Coutellier; C Desmoulins; J P Fadlallah; S Herson; D Valla
Journal:  J Hepatol       Date:  1994-07       Impact factor: 25.083

9.  Essential thrombocythemia at diagnosis: causes of diagnostic evaluation and presence of positive diagnostic findings.

Authors:  R Jantunen; E Juvonen; E Ikkala; K Oksanen; P Anttila; P Hormila; S E Jansson; R Kekomäki; T Ruutu
Journal:  Ann Hematol       Date:  1998-09       Impact factor: 3.673

Review 10.  Budd-Chiari syndrome: illustrated review of current management.

Authors:  John D Horton; Francisco L San Miguel; Fernando Membreno; Francis Wright; Juan Paima; Preston Foster; Jorge A Ortiz
Journal:  Liver Int       Date:  2008-04       Impact factor: 5.828

  10 in total
  1 in total

Review 1.  The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies.

Authors:  Jin Zhang; Cheng Li; Xiaorong Han; Zhongbo Chen; Binay Kumar Adhikari; Yinghui Wang; Yonggang Wang; Jian Sun
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.